SIRT2在膀胱尿路上皮癌中的表达、临床意义及其对癌细胞增殖、侵袭和迁移的影响

doi:10.16352/j.issn.1001-6325.2023.07.1090

基础医学与临床 ›› 2023, Vol. 43 ›› Issue (7): 1090-1096.doi: 10.16352/j.issn.1001-6325.2023.07.1090

SIRT2在膀胱尿路上皮癌中的表达、临床意义及其对癌细胞增殖、侵袭和迁移的影响

金晓霞¹, 陆晓云¹, 刘玉山¹, 梁李娜^2,*

1.南通大学附属肿瘤医院病理科,江苏南通 226000;
2.厦门市海沧医院肾内科,福建厦门 361026

收稿日期:2022-11-04 修回日期:2023-02-17 发布日期:2023-07-05
通讯作者: ^*39594622@qq.com
基金资助:
南通市卫健委面上课题(MB2021045)

Expression and clinical significance of SIRT2 in urothelial bladder cancer and its impact on cancer cell proliferation, invasion and migration

JIN Xiaoxia¹, LU Xiaoyun¹, LIU Yushan¹, LIANG Lina^2,*

1. Department of Pathology, Affiliated Tumor Hospital of Nantong University, Nantong 226000;
2. Department of Nephrology, Haicang Hospital, Xiamen 361026, China

Received:2022-11-04 Revised:2023-02-17 Published:2023-07-05

摘要/Abstract

摘要： 目的探讨沉默信息调节因子2(SIRT2)在膀胱尿路上皮癌(UBC)组织中的表达、临床意义及下调SIRT2后对膀胱癌细胞增殖、侵袭及迁移的影响。方法利用免疫组化EnVision法检测SIRT2蛋白在95例膀胱尿路上皮癌组织和39例癌旁组织中的表达,分析其与临床病理学参数的关系。采用RT-qPCR检测膀胱癌细胞系中SIRT2 mRNA的表达,Western blot检测膀胱癌细胞系、12对膀胱癌组织中SIRT2蛋白的表达。利用慢病毒感染稳定下调膀胱癌细胞系T24中的SIRT2基因。CCK8法及细胞集落实验检测细胞增殖;Transwell小室法检测细胞侵袭及迁移能力。结果 SIRT2在膀胱尿路上皮癌组织中的阳性表达率为84%(80/95),高于正常尿路上皮组织的5%(2/39)(P<0.05)。SIRT2在高级别尿路上皮癌组表达率为95%(38/40),高于低级别组的76%(42/55)(P<0.05);在肌层侵袭组中表达率为96%(24/25),高于非肌层侵袭组的80%(56/70)(P<0.05)。新鲜膀胱癌组织中SIRT2蛋白表达高于癌旁组织。SIRT2的mRNA及蛋白在膀胱癌细胞系中也均表达上调。在T24细胞中敲减SIRT2,细胞增殖、侵袭及迁移能力均明显下降(P<0.05)。结论 SIRT2在膀胱尿路上皮癌中高表达,干扰SIRT2显著抑制膀胱癌细胞增殖、侵袭及迁移。

关键词: SIRT2, 膀胱尿路上皮癌, 免疫组织化学, 增殖, 侵袭及迁移

Abstract: Objective To investigate the expression and clinical significance of silent information regulator 2 (SIRT2) form tissue of urothelial bladder cancer(UBC) and the effects of down-regulation of SIRT2 on the proliferation, invasion and migration of bladder cancer cells. Methods The expression of SIRT2 protein was detected in 95 samples of urothelial bladder cancer tissues and 39 paracancerous tissues using the immunohistochemical EnVision method. Its relationship with clinicopathological parameters was analyzed. The expression of SIRT2 mRNA in bladder cancer cell lines was detected by RT-qPCR, and the expression levels of SIRT2 protein in bladder cancer cell lines, 12 pairs of fresh bladder cancer tissues were detected by Western blot. Lentiviral infection was used to stably downregulate the SIRT2 gene in bladder cancer cell line T24. CCK8 and cell colony assays were performed to detect changes in cell proliferation ability and Transwell assay to detect changes in cell invasion and migration activity. Results The positive expression rate of SIRT2 in urothelial bladder cancer tissues was 84%(80/95), which was higher than that in normal uroepithelial tissues (5%, 2/39) (P<0.05). The expression rate of SIRT2 was higher in the high-grade uroepithelial cancer group (95%, 38/40) than in the low-grade group (76%, 42/55) (P<0.05); The expression rate was higher in the muscle-infiltrated group (96%, 24/25) than in the non-muscle-infiltrated group (80%, 56/70) (P<0.05). Expression of SIRT2 protein was higher in fresh bladder cancer tissues than in normal tissues adjacent to the cancer. Expression of mRNA and protein of SIRT2 were also upregulated in bladder cancer cell lines. Knockdown of SIRT2 in T24 cells resulted in a significant decrease in cell activity of proliferation, invasion and migration (P<0.05). Conclusions SIRT2 is highly expressed in bladder uroepithelial carcinoma, and interfers with SIRT2 significantly and so inhibites bladder cancer cell proliferation, invasion and migration.

Key words: SIRT2, urothelial bladder cancer, immunohistochemistry, proliferation, invasion and migration

中图分类号:

R737.1

金晓霞, 陆晓云, 刘玉山, 梁李娜. SIRT2在膀胱尿路上皮癌中的表达、临床意义及其对癌细胞增殖、侵袭和迁移的影响[J]. 基础医学与临床, 2023, 43(7): 1090-1096.

JIN Xiaoxia, LU Xiaoyun, LIU Yushan, LIANG Lina. Expression and clinical significance of SIRT2 in urothelial bladder cancer and its impact on cancer cell proliferation, invasion and migration[J]. Basic & Clinical Medicine, 2023, 43(7): 1090-1096.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal11.magtechjournal.com/Jwk_jcyxylc/CN/10.16352/j.issn.1001-6325.2023.07.1090

http://journal11.magtechjournal.com/Jwk_jcyxylc/CN/Y2023/V43/I7/1090

参考文献

[1] Lenis AT, Lec PM, Chamie K, et al. Bladder cancer: a review[J]. JAMA, 2020, 324:1980-1991.
[2] 曹毛毛, 陈万青. GLOBOCAN 2020全球癌症统计数据解读[J]. 中国医学前沿杂志(电子版), 2021, 13:63-69.
[3] 白冰, 张海芳, 杨庆良, 等. 下调lncRNA RHPN1-AS1抑制人膀胱癌细胞系T24增殖和迁移[J]. 基础医学与临床, 2022, 42:940-944.
[4] W?troba M, Dudek I, Skoda M, et al. Sirtuins, epigenetics and longevity[J]. Ageing Res Rev, 2017, 40:11-19.
[5] Wang Y, Yang J, Hong T, et al. SIRT2: controversy and multiple roles in disease and physiology[J]. Ageing Res Rev, 2019, 55:100961. doi: 10.1016/j.arr.2019.100961.
[6] Liu HY, Liu YY, Yang F, et al. Acetylation of MORC2 by NAT10 regulates cell-cycle checkpoint control and resistance to DNA-damaging chemotherapy and radiotherapy in breast cancer[J]. Nucleic Acids Res, 2020, 48:3638-3656.
[7] Li C, Zhou Y, Kim JT, et al. Regulation of SIRT2 by Wnt/beta-catenin signaling pathway in colorectal cancer cells[J]. Biochim Biophys Acta Mol Cell Res, 2021, 1868:118966. doi: 10.1016/j.bbamcr.2021.118966.
[8] Zhu H, Hu Y, Zeng C, et al. The SIRT2-mediated deacetylation of AKR1C1 is required for suppressing its pro-metastasis function in non-small cell lung cancer[J]. Theranostics, 2020, 10:2188-2200.
[9] Aventaggiato M, Vernucci E, Barreca F, et al. Sirtuins’ control of autophagy and mitophagy in cancer[J]. Pharmacol Ther, 2021, 221:107748. doi: 10.1016/j.pharmthera.2020.107748.
[10] Jin X, Wei Y, Xu F, et al. SIRT1 promotes formation of breast cancer through modulating Akt activity[J]. J Cancer, 2018, 9:2012-2023.
[11] Liu CW, Lin YC, Hung CM, et al. CHM-1, a novel microtubule-destabilizing agent exhibits antitumor activity via inducing the expression of SIRT2 in human breast cancer cells[J]. Chem Biol Interact, 2018, 289:98-108.
[12] Kim HS, Vassilopoulos A, Wang RH, et al. SIRT2 maintains genome integrity and suppresses tumorigenesis through regulating APC/C activity[J]. Cancer Cell, 2011, 20:487-499.

[1]	张培波. 沙棘总黄酮通过miR-144/PI3K/Akt信号通路抑制膀胱癌细胞的增殖并促进细胞凋亡的分子机制研究[J]. 基础医学与临床, 2023, 43(7): 1122-1126.
[2]	唐一君, 王文龙, 李江丽, 杨欢, 孙静. LncRNA RP11-686D22.10与乳腺癌患者生存期相关并影响乳腺癌细胞系的增殖和侵袭[J]. 基础医学与临床, 2023, 43(7): 1023-1029.
[3]	曾燕坤洪小颖陈清林. 下调BECN1抑制人白血病细胞系THP-1增殖、侵袭和迁移[J]. 基础医学与临床, 2023, 43(7): 1104-1109.
[4]	苏靓誉, 张振西, 杜文静. TPX2的表达对胰腺癌预后的影响[J]. 基础医学与临床, 2023, 43(6): 875-881.
[5]	侯孟杰, 赵娜, 黄富强, 王亚南, 刘芳铭. 载脂蛋白E通过降低高尔基体膜蛋白73表达抑制小鼠肝癌细胞系增殖[J]. 基础医学与临床, 2023, 43(5): 762-770.
[6]	刘月, 曹阳, 顾伟英, 商丽梅, 刘琰. 地西他滨联合三氧化二砷抑制急性髓系白血病细胞系增殖和促进凋亡[J]. 基础医学与临床, 2023, 43(4): 608-614.
[7]	王芳芳, 曹慧媛, 汪婧, 王宁, 黄国良. 上调miR-200c-5p的表达抑制人结直肠癌细胞系SW480增殖[J]. 基础医学与临床, 2023, 43(2): 241-245.
[8]	杨良权, 于淼, 姜茜, 张明慧, 杨海松. miR-504调控蛋白酶体激活因子抑制人乳腺癌细胞系MCF-7增殖及迁移[J]. 基础医学与临床, 2023, 43(1): 95-101.
[9]	贺晶, 李艳, 王延峰, 鲍慧. FABP4表达上调促进人子宫内膜癌细胞系HEC-1-A增殖和迁移[J]. 基础医学与临床, 2022, 42(9): 1356-1361.
[10]	张晓雷, 刘静, 李朝萍. Circ_0032821参与索拉非尼抑制乳腺癌细胞系T47D增殖、迁移和侵袭[J]. 基础医学与临床, 2022, 42(9): 1350-1354.
[11]	王娟, 张晓燕, 朱爱华, 于宏波, 范新丹, 汤春辉, 姚秀芳. Ku70高表达促进人卵巢癌细胞系的增值并与卵巢癌患者不良预后相关[J]. 基础医学与临床, 2022, 42(9): 1391-1399.
[12]	沈永华, 汪峻峰, 程泽星, 冯娟娟. 秦皮甲素抑制人鼻咽癌细胞系HNE-3增殖[J]. 基础医学与临床, 2022, 42(8): 1237-1242.
[13]	谢思安, 陈奕阳, 徐俊玄, 宁婷婷, 张楠, 朱圣韬, 张澍田. PTOV1表达水平对结直肠癌患者预后的影响[J]. 基础医学与临床, 2022, 42(8): 1176-1181.
[14]	江宁, 郭钧, 刘铖, 周举. 莪术醇抑制人骨肉瘤细胞系的增殖和促凋亡[J]. 基础医学与临床, 2022, 42(8): 1200-1205.
[15]	刘磊, 李世宝, 张好良. 沉默lnc-SLC2A12-10:1抑制人胃癌细胞系AGS增殖、迁移和侵袭[J]. 基础医学与临床, 2022, 42(7): 1071-1076.

SIRT2在膀胱尿路上皮癌中的表达、临床意义及其对癌细胞增殖、侵袭和迁移的影响

Expression and clinical significance of SIRT2 in urothelial bladder cancer and its impact on cancer cell proliferation, invasion and migration

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价